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associated variants for regulatory activity
Jason C. Klein 1,5, Aidan Keith1,5, Sarah J. Rice2, Colin Shepherd2, Vikram Agarwal1, John Loughlin2 &
Jay Shendure 1,3,4
To date, genome-wide association studies have implicated at least 35 loci in osteoarthritis
but, due to linkage disequilibrium, the specific variants underlying these associations and the
mechanisms by which they contribute to disease risk have yet to be pinpointed. Here, we
functionally test 1,605 single nucleotide variants associated with osteoarthritis for regulatory
activity using a massively parallel reporter assay. We identify six single nucleotide poly-
morphisms (SNPs) with differential regulatory activity between the major and minor alleles.
We show that the most significant SNP, rs4730222, exhibits differential nuclear protein
binding in electrophoretic mobility shift assays and drives increased expression of an alter-
native isoform of HBP1 in a heterozygote chondrosarcoma cell line, in a CRISPR-edited
osteosarcoma cell line, and in chondrocytes derived from osteoarthritis patients. This study
provides a framework for prioritization of GWAS variants and highlights a role of HBP1 and
Wnt signaling in osteoarthritis pathogenesis.
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Osteoarthritis (OA) is a chronic disease of the articulatingjoints, characterized by the degradation of articular car-tilage, synovial inflammation, and remodeling of the
subchondral bone. This leads to a debilitating impairment of joint
function. OA is the most common cause of disability in adults
over the age of 60, and it is predicted that by 2050, it will affect
over 130 million individuals worldwide1. Genetic factors com-
prise ~50% of an individual’s total risk of developing the disease.
A series of genome-wide association studies (GWAS) have been
carried out in OA and have identified 35 independent genetic
signals for disease susceptibility. Outside of OA, GWAS have
successfully implicated thousands of genetic loci in a wide range
of common human diseases. Most of the underlying signal is
believed to derive from variation in non-coding regulatory
sequences. However, because of linkage disequilibrium (LD), it
has been extraordinarily challenging for the field to identify the
variants that causally underlie each association.
Over the past decade, we and others developed massively
parallel reporter assays (MPRAs) to increase the throughput at
which regulatory sequences can be tested for functional poten-
tial2–5. An MPRA involves cloning thousands of candidate reg-
ulatory sequences to a single reporter gene, transfecting them to a
cell line en masse, and performing deep sequencing of the
resulting transcripts to quantify the degree of transcriptional
activation mediated by each candidate regulatory sequence.
MPRAs have previously been applied to characterize variants
underlying eQTLs (in LCLs)6, red blood cell traits (in K562 and
human erythroid progenitors/precursors)7, cancer-associated
common variants (in HEK293 cells)8, and adiposity-associated
common variants (in HepG2 cells9).
Here, we apply an MPRA (specifically, STARR-seq5) to
quantify the relative regulatory potential of SNPs residing on
haplotypes implicated in (OA), prioritizing six out of 1,605 SNPs
with differential regulatory activity. The most significant SNP,
rs4730222 falls within an alternative TSS of HBP1, shows dif-
ferential nuclear protein binding, and leads to increased expres-
sion of an alternative isoform(s) of HBP1 in several systems.
Results
MPRA to prioritize regulatory GWAS variants. We compiled a
list of 35 lead SNPs associated with OA in Europeans via GWAS,
with minor allele frequencies over 5%10–27. Each SNP represents
an independent signal with p < 5e-8 (genome-wide significant;
n= 20) or p < 5e-5 (genome-wide suggestive; n= 15) (Supple-
mentary Table 1). We identified all SNPs in LD with an r2 > 0.8 in
Europeans using rAggr (Fig. 1a), resulting in a list of 1,605
candidate SNPs. For the major and minor allele of each SNP, we
synthesized 196 nucleotides (nt) of genomic sequence, centered
on the SNP and flanked by adaptor sequences, on a microarray
(230 nt oligos; Fig. 1b; Supplementary Data 1).
In order to increase quantitativeness of the assay, we modified
STARR-seq by incorporating five nt degenerate barcodes during
PCR amplification of array-derived oligonucleotides, i.e., prior to
cloning. This modification allowed us to effectively make multiple
independent measurements (unique barcode–allele combina-
tions) of each allele in a single experiment (Fig. 1c)5. We then
cloned these barcoded oligos into the human STARR-seq vector
and transfected Saos-2 cells, an osteosarcoma cell line, in
triplicate. Importantly, in STARR-seq, the candidate regulatory
sequences are located within the transcript itself, rather than
upstream of the promoter as in a conventional reporter assay
(Fig. 1d). From the transfected Saos-2 cells, we extracted,
amplified, and sequenced both DNA and RNA corresponding
to the cloned region, and then calculated activity scores as the
normalized log2 (proportion of RNA reads/proportion of DNA
reads) for each barcode–allele combination (Fig. 1e, f). For all
alleles with at least three independent barcodes (i.e., a
barcode–allele pair in any of the three replicates), we averaged
the allele activity scores to a single value. Due to bottlenecking
during library construction, some alleles were under sampled and
therefore excluded from further analysis. Altogether, we obtained
activity scores for 2,537 of 3,210 alleles (79%; avg. 12.9
measurements per allele) (Supplementary Data 2), and activity
scores for both alleles of 1,132 of 1,605 SNPs (70%; avg. 13.4
measurements per allele) (Supplementary Data 3). Enrichment
scores were highly correlated between independent transfections,
with Spearman rho’s ranging from 0.82 to 0.9 and Pearson r’s
ranging from 0.85 to 0.93 (Fig. 2a; Supplementary Data 4).
Enrichment of regulatory marks in MPRA active sequences.
We first asked whether these STARR-seq-based activity scores
correlated with biochemical marks for putative enhancers. For
this analysis, we looked at all major alleles with at least three
independent barcodes (n= 1,254). We ranked these major alleles
into quintiles, and then intersected these with data sets of bio-
chemical marks of putative enhancers in cartilage and bone
(H3K27ac in bone marrow-derived chondrocytes, H3K27ac in
the human embryonic limb buds, and ATAC-seq in knee OA
cartilage)28,29 (Supplementary Fig. 1). The highest scoring
quintile was significantly enriched for overlap with H3K27ac
ChIP-seq peaks in embryonic limb bud from E41 (2.1-fold,
Bonferroni-corrected chi-square p= 0.035), E44 (2.0-fold,
Bonferroni-corrected chi-square p= 0.031), and E47 (2.3-fold,
Bonferroni-corrected chi-square p= 0.0039), relative to all other
major alleles. While the trend remained, there was neither a
significant enrichment in knee OA cartilage ATAC-seq peaks
(1.7-fold) nor bone marrow-derived chondrocyte H3K27ac peaks
(1.4-fold). The highest scoring quintile includes 251 genomic
regions, 65 of which overlap putative enhancers from at least one
data set. In contrast, the lowest scoring quintile includes 250
genomic regions, only 37 of which overlap putative enhancers
from at least one data set (1.7-fold enrichment, chi-square p=
2.0e-3). Altogether, these enrichments demonstrate that at least a
subset of the 1,605 genomic regions tested here correspond to
enhancers in OA-relevant tissues.
To evaluate whether these enrichments were specific to bone
and cartilage, we similarly tested for overlap with H3K27ac ChIP-
seq peaks in H1-hESCs, HeLa, HepG2, Gm12878, K562, and
HSMM cell lines. We identified significant enrichment in H1-
hESC (1.5-fold, Bonferroni-corrected chi-square p= 0.0021),
HeLa (1.8-fold, Bonferroni-corrected chi-square p= 0.0038),
and HepG2 (1.6-fold, Bonferroni-corrected chi-square p=
0.023) cells, and non-significant trends in Gm12878 (1.5-fold),
K562 (1.3-fold), and Hsmm (1.1-fold). Although weaker in
magnitude than the overlap with embryonic limb bud H3K27ac
ChIP-seq peaks, these trends suggest that many of the tested
genomic regions are not cell-type specific.
To our knowledge, this data set is the largest functional screen
for enhancers in an osteosarcoma cell line. Therefore, we asked
whether we could use our data to identify TFs that contribute to
enhancer activity in bone. Toward the goal of predicting the
enhancer activity of the major allele, we trained a tenfold cross-
validated lasso regression model that considered 853 evolution-
ary, biochemical, and sequence-derived features (Supplementary
Data 5). The predictions of our model correlated to the observed
enhancer activity scores with a Spearman rho of 0.28 (Supple-
mentary Fig. 2A). Training the lasso regression model on the
entire data set, 76 total features were selected by the model
(Supplementary Data 6, Supplementary Table 2). The 30 top
features, which include both histone marks and TF-binding
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Fig. 1 Schematic of massively parallel reporter assay. a For each GWAS-lead SNP, we identified all SNPs in LD with r2 > 0.8. Colored lines indicate SNPs in
the same LD block. b For all SNPs, we extracted 196 nt of genomic sequence centered at the SNP, and separately synthesized the minor (hollow circle) and
major alleles, flanked by common adaptor sequences (cyan and purple). c, d We amplified our library from the array via PCR with primers directed at the
common adaptors, in the process appending five nt degenerate barcodes (black lines) and additional sequences homologous to the vector (cyan). We
cloned our barcoded library of all major and minor alleles into the STARR-seq vector. Each putative regulatory region is cloned into the 3′-UTR of a reporter
gene (cyan) with a minimal promoter (dark blue). eWe transfected our library into Saos-2 cells via electroporation. Forty-eight hours post transfection, we
extracted RNA and DNA. f We determined the abundance of each allele–barcode combination in the mRNA and DNA population through sequencing. For
each allele, we calculated one activity score as the average log2(RNA/DNA) across all independent measurements
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Fig. 2 Pairwise correlations between replicates and identification of alleles with differential regulatory activity. a Pairwise correlation of RNA/DNA ratios
between three replicates. The lower left triangle shows pairwise scatter plots. The diagonal provides replicate names and the respective histogram of the
RNA/DNA ratios for that replicate. The upper triangle provides Pearson (rho) and Spearman (r) correlation coefficients. b Scatter plot of the major versus
minor allele for each SNP. Six SNPs with differential regulatory activity (indicated by colors in the legend) were identified using a Mann–Whitney U Test
with an FDR of 10%. Source data are provided as a Source Data file
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predictions of the corresponding genomic regions, are shown in
Supplementary Fig. 2B.
Differential regulatory activity of SNPs in MPRA. We next
sought to ask whether any alleles are differentially active, focusing
on the 1,132 SNPs for which we successfully measured activity
scores for both alleles (Supplementary Data 2). Overall, activity
scores for two alleles of a given SNP were highly correlated, with
an overall Spearman correlation of 0.744 (Fig. 2b). This was
reassuring, given that each pair of alleles was separately synthe-
sized and cloned, and therefore present at non-identical abun-
dances in the STARR-seq library. After correcting for multiple
testing with Benjamini–Hochberg (BH) at a 10% FDR, we iden-
tified six SNPs whose alleles demonstrated significantly differ-
ential functional activity in Saos-2 cells (Fig. 2b; Supplementary
Data 2). The most significant SNP, rs4730222, is located in the 5′-
UTR of several non-canonical isoforms of HMG-Box transcrip-
tion factor 1 (HBP1). Other significant SNPs include rs2286798
(intronic to ITIH1), rs6976 (3′-UTR of GLT8D1), rs114009236
(intronic to SUPT3H), rs80095766 (intronic to COG5), and
rs6088799 (intronic to UQCC). Two pairs of the six significant
SNPs are at the same loci (the ones near HBP1 and COG5, both at
chromosome 7q22.3; and the ones near ITIH1 and GLT8D1, both
at chromosome 3p21.1). To further validate these six SNPs, we
tested each of the six in a conventional luciferase-based enhancer
assay, also in Saos-2 cells. The results for rs4730222 and
rs6088799 were concordant with STARR-seq results, while the
results for rs80095766 also showed differential activity, but in the
opposite direction to STARR-seq. The other three SNPs did not
demonstrate significantly differential activity.
Three of the six SNPs (notably the three with the most
significant differential expression) are predicted to disrupt protein
binding by RegulomeDb, compared with 117/1,126 of the
remaining SNPs (p= 1.67e-3, chi-square). rs4730222 is predicted
to disrupt binding of several proteins based on ChIP-seq,
including POLR2A (Supplementary Data 7). rs2286798 disrupts
an En1 motif, and serves as an eQTL for WDR51A, FLJ12442,
ITIH3, and NT5DC2 in lymphoblastoid cells and FLJ12442 and
ITIH4 in monocytes (Supplementary Table 3). rs6976 is predicted
to disrupt binding of several proteins based on ChIP-seq,
including POLR2A and EP300 (Supplementary Table 4). It is
also an eQTL for WDR51A, FLJ12442, and NT5DC2 in
lymphoblastoid cells and FLJ12442 and ITIH4 in monocytes.
Validation and characterization of rs4730222. We chose to
further characterize rs4730222 for several reasons. First, this SNP
was the most significant hit from our reporter assay, with a
substantial difference in activity between the two alleles (2.5-fold
increased expression of the minor, disease-associated allele; BH-
adjusted p-value= 8.8e-5). Second, its differential activity was
confirmed by a conventional luciferase-based enhancer assay
(2.02-fold, Wilcoxon matched-pairs signed rank test p < 1e-4).
Third, of the six, only rs4730222 overlaps with putative enhancer
marks in embryonic limb buds (H3K27ac) and osteoarthritic
knee cartilage (ATAC-seq). Fourth, we had previously prioritized
HBP1 as a potential target in the 7q22 osteoarthritis-associated
locus based on gene expression analysis30. HBP1 is a transcrip-
tional repressor that regulates the Wnt-beta–catenin pathway as
well as superoxide production, both of which have been impli-
cated in OA development and progression31–33.
rs4730222 overlaps with several marks associated with active
regulatory DNA: H3K27ac (mark for active enhancers and
promoters) from bone marrow-derived chondrocytes29, human
embryonic limb bud at E33, E41, E44, and E4728, and ENCODE
layered data; H3K4me3 (mark for active promoters) in ENCODE
layered data; and ATAC-seq (mark for open chromatin) peaks
from articular knee cartilage of OA patients34 (Fig. 3a). HBP1
contains several transcript isoforms, with three probable alter-
native promoters identified from cap-selected clones and nine
validated alternative polyadenylation sites35. One of the three
probable alternative promoters contains rs4730222 at position+
80 relative to the alternative transcriptional start site (TSS). We
therefore hypothesized that the variant may alter expression of
this or another HBP1 isoform. To test this, we first confirmed that
the alternative TSS overlapping rs4730222 is utilized in Saos-2
and SW1353 cells (a chondrosarcoma cell line) with qRT-PCR
with primers contained within this 5′-UTR as well as spanning to
the following exon. However, despite multiple attempts, we failed
to successfully amplify the isoform from the alternative TSS to the
canonical stop, suggesting that the alternative TSS may belong to
a truncated isoform of the HBP1 transcript. Based on PCR and
Sanger sequencing, the truncated isoform is most likely
ENST00000497535, which contains the alternative 5′-UTR and
first two exons (Fig. 3a; Supplementary Fig. 3).
After confirming that rs4730222 is transcribed as part of a
HBP1 isoform in osteogenic and chondrogenic cells (albeit not to
the canonical stop), we genotyped rs4730222 in several cell lines
(SW1353, Tc28a/2, Saos-2, chondrogenic progenitor cells) in
hopes of identifying a heterozygous line. As SW1353 was
heterozygous for rs4730222, we tested it for allelic expression
imbalance (AEI) of the transcribed SNP. In all three biological
replicates, we observed a significant allelic imbalance (Fisher’s
exact test, p < 1e-5), with the minor allele showing a 1.3 to 1.4-
fold relative enrichment in RNA/DNA compared with the major
allele. This was more modest but directionally concordant with
2.5-fold enrichment of the minor allele in the reporter assay
(Fig. 3b).
The OA-implicated haplotype at 7q22.3 is a ~500 -kb region of
high-linkage disequilibrium, and consequently accounts for 283
of the 1,605 SNPs tested here. The observed AEI of the HBP1
alternative isoform in SW1353 cells, which are likely hetero-
zygous for the entire OA-associated haplotype, could be
consequent to any or several of these SNPs, or to other forms
of genetic variation. To test whether rs4730222 causally underlies
the allelic imbalance of the HBP1 alternative transcript, we
introduced the minor allele of rs4730222 into Saos-2 cells, which
are homozygous for the major allele, through CRISPR-mediated
homology directed repair (HDR). We generated four biological
replicates (i.e., independently edited cell populations), and
quantified the RNA/DNA ratio of indel-free reads derived from
the major versus minor allele. Similar to the SW1353 AEI (1.3 to
1.4-fold), we identified a 1.4 to 1.6-fold relative enrichment in the
RNA/DNA ratio for the minor allele compared with the major
allele (Fisher’s exact test, p < 1e-5; Fig. 3c). This confirms that the
minor allele at rs4730222 causally underlies upregulation of the
HBP1 alternative isoform.
We next sought to test whether rs4730222 is associated with
different levels of the HBP1 alternative isoform in osteoarthritic
tissue. To do so, we tested for AEI in chondrocytes derived from
OA patients. For each of nine patients heterozygous for
rs4730222, we extracted RNA and DNA and amplified and
sequenced the 5′-UTR containing the SNP (three technical
replicates per patient) from DNA and cDNA. Despite low cDNA
concentrations and low expression of the alternative TSS, we
observed an overall trend in AEI in accordance with our reporter
assay and cell models (median AEI= 1.06, Mann–Whitney U-test
on 9 DNA ratios vs. 9 RNA ratios, p= 0.008). Interestingly, one
patient appeared to exhibit AEI in the opposite direction36,37
(Supplementary Fig. 4).
Finally, in order to test whether rs4730222 is driving
differential expression through TF binding, we performed EMSA
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experiments using nuclear protein from both Saos-2 and
SW1353. For both cell types, we identified reproducible
differential binding of multiple protein complexes, with greater
binding for the major, G allele (Supplementary Fig. 5).
Speculating that its effect might be on the promoter of the
alternative isoform of HBP1, we subjected the same fragment
containing rs4730222 from the luciferase-based enhancer assay to
a conventional luciferase-based promoter assay. We once again
observed significant, differential expression of the two alleles, but
to our surprise the directionality of effect was opposite to that of
the luciferase-based enhancer assay, the STARR-seq experiment,
as well as all of the other aforementioned experiments, suggesting
that in this context, the regulatory element containing the SNP
acts as an enhancer rather than promoter (Supplementary Fig. 6).
In sum, multiple independent lines of directionally consistent
evidence, including the STARR-seq MPRA, predicted protein
binding, observations of AEI in both a chondrosarcoma cell line
and OA patient chondrocytes, as well as with CRISPR/Cas9-
mediated introduction of the exact allele into an osteosarcoma
cell line, and finally direct demonstration of differential protein
binding, all support the case for rs4730222 as having differential
regulatory activity between the major and minor alleles, likely by
impacting expression of an alternative isoform of HBP1. Of note,
testing rs4730222 in enhancer versus promoter luciferase-based
assays yielded directionally discordant results, highlighting the
importance of context in reporter assays.
Discussion
In summary, we set out to functionally test the regulatory effects
of 1,605 SNPs that potentially underlie 35 GWAS signals for
osteoarthritis. We succeeded in generating reproducible
measurements of differential regulatory activity for almost three
quarters of the regions tested. While this data set captures most
SNPs around our GWAS candidates, due to technological lim-
itations, it is possible that potentially causal variants in these
regions were not included in our assay. The most highly active
regions in our assay were ~2-fold enriched for biochemical marks
associated with enhancers. Considering over 800 features, we
built a predictive model of enhancer activity in Saos-2, whose
predictions correlated with the observed enhancer activity scores
with a Spearman rho of 0.28. Some of the top features include
FLI1 and p53, which have been associated with Ewing’s sarcoma
and osteosarcoma, respectively. NR2F1, a transcriptional repres-
sor that is overexpressed in bone38, was negatively correlated with
enhancer activity (Supplementary Fig. 2B). Surprisingly, the top
predictor was H3K27me3, which is conventionally associated
with heterochromatin. One possible explanation is that the
Polycomb repressive complex 2 (PRC2), which mediates the
introduction of this mark, is frequently dysregulated in osteo-
sarcoma cell lines39. An alternative explanation is that these
elements are being tested outside of their native chromosomal
context, and may act as poised enhancers in the genome. A
further caveat is that the cell types in which the ChIP-seq data
were generated (e.g., osteoblasts and EWS502 for H3K27me3) are
not identical to the cell line in which the MPRA data were gen-
erated (i.e., Saos-2).
We identified six SNPs that were reproducibly associated with
differential expression in the STARR-seq assay at an FDR of 10%,
three of which are predicted to alter protein binding. The most
significant of these, rs4730222, resides in the 5′-UTR of multiple
isoforms of HBP1, a transcriptional repressor. The minor, OA-
associated risk allele of rs4730222 appears to functionally underlie
increased transcriptional levels of alternative isoform(s) of HBP1.
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Fig. 3 Functional validation of rs4730222. a Gene model of HBP1 ensemble isoform ENST00000468410 (major) and ENST00000497535 (alternative).
UCSC genome browser zoomed in to the two transcriptional start sites57. Rs4730222, within the 5′-UTR of the alternative transcript, is indicated by a
vertical gray line traversing the annotation tracks. The four black tracks are H3K27ac performed in human embryonic limb bud at E33, E41, E44, and E47,
respectively28. The green track is H3K27ac data from chondrocytes derived from cultured bone marrow mesenchymal stem cells29. Layered H3K27ac is
H3K27ac ChIP-seq (a marker for active enhancers and active promoters) layered from GM12878, H1-hESC, HSMM, HUVEC, K562, NHEK, and NHLF cells.
Layered H3K4me3 is H3K4me3 ChIP-seq (marker for active promoters) layered from the same seven ENCODE cell lines. b Allelic expression imbalance in
SW1353, a chondrosarcoma cell line heterozygote for rs4730222. Black bars represent the fraction of the minor allele in DNA, and gray bars indicate the
fraction of the minor allele in cDNA. n= 3 independent experiments. c Allelic expression imbalance in Saos-2 cells with the minor allele of rs4730222
introduced through CRISPR-mediated HDR. Bars are the same as in Fig. 3B. n= 4 independent experiments. Source data are provided as a Source Data file
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This conclusion is supported by multiple lines of evidence,
including the STARR-seq MPRA, observations of AEI in both a
chondrosarcoma cell line and OA patient chondrocytes, and
CRISPR/Cas9-mediated introduction of the exact allele into an
osteosarcoma cell line. Notably, testing a fragment containing
rs4730222 in a enhancer luciferase-based assay yielded a result
that was directionally concordant with all other experiments,
while testing the same segment in a promoter assay yielded a
directionally opposite effect. In our view, the directionality
observed with the CRISPR/Cas9-mediated introduction of the
exact allele takes primacy, as it reflects the native chromosomal
context and furthermore isolates the SNP in question from other
SNPs in linkage disequilibrium.
We further demonstrated that the SNP at rs4730222 results in
differential protein binding in both osteosarcoma and chon-
drosarcoma cells, suggesting a mechanism for the differential
expression. As we note more binding at the major G allele, which
results in decreased expression of the alternative HBP1 transcript,
we propose that the C allele is displacing a transcriptional
repressor. There are several potential transcriptional repressors
bound at rs4730222 in different cell lines based on ChIP-seq data,
including ZBTB7A, YY1, MAX, GTSAP30, NFKB1, and ZBTB33.
Of note, ZBTB33 has previously been noted to repress non-
canonical Wnt signaling40. The full list of ChIP-seq peaks at
rs4730222 identified from RegulomeDb is provided as Supple-
mentary Data 7.
We performed our assay in Saos-2 cells, an osteosarcoma cell
line. Therefore, our enrichment scores are a function of this
particular trans environment. Although OA is characterized by
the loss of articular cartilage, there are concurrent pathological
changes to other joint tissues, including bone, making an osteo-
sarcoma cell line relevant to OA pathogenesis41. These take the
form of subchondral sclerosis and the generation of osteophytes.
Furthermore, there is growing evidence that aberrant develop-
ment of the joint, including in the transition from articular
chondrocyte to hypertrophic chondrocyte and the subsequent
ossification of the cartilage, also predisposes to OA42. Moreover,
we validated the AEI and differential protein binding of our lead
SNP, rs4730222 in both Saos-2 and SW1353, a chondrosarcoma
cell line, suggesting that this particular finding is relevant to both
bone and cartilage-derived cells.
We propose that rs4730222 is contributing to osteoarthritis
by disrupting the tightly regulated Wnt signaling pathway.
Wnt signaling plays a key role in joint development43, as well as
in joint destruction in the form of osteoarthritis44. The Wnt
pathway is tightly regulated in both bone and cartilage, in order
to allow for proper joint development and homeostasis45.
Too little Wnt signaling disrupts both cartilage maintenance
and subchondral bone homeostasis, and contributes to OA in
animal models45,46. Similarly, excess signaling also triggers
disease, and leads to an OA phenotype in mice47. HBP1 acts
as a negative regulator of the Wnt-beta–catenin pathway48,
and therefore its altered expression secondary to rs4730222
may disrupt the tight regulation of Wnt signaling and
predispose to OA.
While we demonstrate a functional role for rs4730222 on
HBP1 expression, further experiments are needed to directly
implicate rs4730222 in Wnt signaling and OA pathogenesis. In
this work, we edited the rs4730222 allele in Saos-2 in a bulk
population and differentiated the editing outcomes through
sequencing. Looking forward, it will be necessary to generate
monoclonally edited cell lines, e.g., in Saos-2 and SW1353, to
perform further functional investigation of the role of this variant.
For example, the functional consequences of the variant could be
examined through transcriptome sequencing and pathway ana-
lysis, or its potential impact in Wnt signaling and/or OA
pathogenesis analyzed through the TCF/LEF reporter assay or
qPCR of marker genes.
We previously described reduced expression of the canonical
HBP1 transcript in OA tissue, relative to healthy tissue30. How-
ever, the increased expression was not consistently linked to a
specific allele, suggesting that it may be driven by a trans-acti-
vating factor, rather than a cis-regulatory element. Furthermore,
our findings here pertain to an alternative isoform of HBP1, not
the canonical transcript. Indeed, we do not observe AEI of the
canonical HBP1 transcript, but rather only of the alternative
isoform.
We speculate that the impact of rs4730222, wherein the
disease-associated allele increases expression of an alternative
transcript, secondarily reduces expression of canonical HBP1.
One possibility is that the alternative isoform encodes a non-
coding RNA with an upstream open-reading frame (uORF). This
isoform of HBP1 may have a trans effect on the canonical tran-
script, or have its own, yet uncharacterized, function in the cell. In
addition, alternative TSSs have been shown to modulate trans-
lational efficiency and tissue specificity of genes49,50. Through one
or several of these mechanisms, the expression levels of this
isoform might modulate HBP1 levels in certain tissues. Finally,
we note that the rs4730222-overlapping isoform expressed in
SW1353 and Saos-2 is a truncated version of HBP1. Therefore, it
may disrupt endogenous activity of the protein, e.g. by acting as a
dominant negative. Distinguishing between these mechanistic
possibilities for rs4730222 and HBP1, as well as for other MPRA-
prioritized OA-associated SNPs, should be a high priority for
the field.
Methods
Identification and design of target SNPs. We selected SNPs that had a minor
allele frequency >5% and had been reported as being associated with OA in Eur-
opean populations at a significance level that surpassed or approached the genome-
wide threshold of <5e-8. The deadline date for inclusion was May 2017. In total, 35
SNPs were identified, each representing an independent association signal (Sup-
plementary Table 1). We ran rAGGr on our list of 35 candidate SNPs to identify all
variants with a minimumminor allele frequency >= 0.001 in linkage disequilibrium
with an r2 > 0.8 in Europeans (CEU+ FIN+GBR+ IBS+ TSI) based on 1000
Genomes, Phase 3, Oct 2014. We then filtered out any polymorphisms greater than
one nucleotide, resulting in a list of 1,605 SNPs. For each variant, we extracted 196
nt of genomic sequence centered around the SNP using BEDTOOLS getfasta, and
edited the SNP to create both the minor and major alleles (3,210 sequences). To
each 196 nt sequence, we appended HSS_clon_F (5′-TCTAGAGCATGCACCGG-
3′) to the 5′ end and DO_R6 (5′-GCCGGTCAGAATGATGG-3′) to the 3′ end. We
then ordered the 3,210 sequences in duplicate as part of an Agilent 244 K 230-
mer array.
Library generation. We amplified our sequences off of the Agilent array with
HSS_clon_F and R6_5N_HSSR (5′-CCGGCCGAATTCGTCGANNNNNCCATC
ATTCTGACCGGC-3′) using KAPA HiFi HotStart ReadyMix in a 50 µL reaction
with 0.75 ng of DNA and SYBR Green on a MiniOpticon Real-Time PCR system
(Bio-Rad) and stopped the reaction before plateauing (13 cycles). This reaction
amplified our library, added a five nt degenerate barcode to each sequence, and
added both adapters for cloning into the human STARR-seq vector. We purified
the PCR product using a 1.5x AMPure cleanup following manufacturer’s protocol.
We then ligated 6 ng of our purified PCR into 25 ng of linearized human STARR-
seq backbone using the NEBuilder HiFi DNA Assembly Cloning Kit following the
manufacturer’s protocol. We transformed 1.2 µL of the ligation product in 50 µL of
NEB C3020 cells, grew up overnight in 100 mL of LB+Amp, and extracted the
library using a Zymo Research ZymoPURE Plasmid Midiprep Kit.
STARR-seq screen. We transfected 1.5 million Saos-2 cells (ATCC) with 20 µg of our
library in triplicate using the Thermo Fisher Scientific Neon Transfection System with
resuspension buffer R at 1250V, 40ms, 1 shock, with 100 µL pipettes, in triplicate. After
electroporation, we added the cells to 10 -cm plates with pre-warmed media (McCoy’s
5 A with 10% FBS and 1x Pen/Strep). Forty-eight hours post transfection, we extracted
both DNA and RNA from each replicate using the Qiagen ALLPrep DNA/RNA Mini
Kit. DNA was eluted in 80 µL and RNA was eluted in 30 µL. RNA was treated with
Thermo Fisher Scientific TURBO DNase following the manufacturer’s protocol and
reverse transcribed using Thermo Fisher Scientific SuperScript III Reverse Transcriptase
in a 20 µL reaction with 8 µL of RNA. For each replicate, we amplified DNA in two
reactions, each with 2 µg of DNA using NEBNext High Fidelity 2X PCR Master Mix
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with primers HSS_NF_pu1 (5′-CTAAATGGCTGTGAGAGAGCTCAGGTACAACT
GATCTAGAGCATGCACC-3′) and HSS_R_pu1 (5′-ACTTTATCAATCTCGCTCCA
AACCCTTATCATGTCTGCTCGAAGC-3′), and stopped before plateauing (15
cycles). After PCR, products were purified with a 1.5x AMPure cleanup, and pooled
together. For each replicate, we also amplified cDNA in two reactions, each with 10 µL
of RT product in 50 µL reactions with NEBNext High Fidelity 2X PCRMaster Mix with
primers HSS_F_pu1 (5′- CTAAATGGCTGTGAGAGAGCTCAGGGGCCAGCTGTT
GGGGTGTCCAC-3′) and HSS_R_pu1 (5′- ACTTTATCAATCTCGCTCCAAACCC
TTATCATGTCTGCTCGAAGC-3′), and stopped before plateauing (18–20 cycles).
After PCR, products were purified with a 1.5x AMPure cleanup, eluted in 50 µL each,
and pooled together. For the cDNA samples, we performed a nested reaction using
KAPA HiFi HotStart ReadyMix in a 50 µL reaction with 1 µL of the pooled outer PCR
reaction with HSS-NF-pu1 and pu1R (5′-ACTTTATCAATCTCGCTCCAAACC-3′),
and stopped before plateauing (7 cycles). Reactions were purified with a 1.5x AMPure
cleanup and eluted in 50 µL each. Flow cell adapters and indexes were added to all
DNA and cDNA reactions through an additional round of PCR using Kapa HiFi
HotStart ReadyMix in 50 µL reactions with 1 µL of the first DNA PCR or 1 µL of the
inner cDNA PCR using an indexed pu1_P5 primer (5′-AATGATACGGCGACCACC
GAGATCTACACNNNNNNNNNNACGTAGGCCTAAATGGCTGTGAGAGAGCT
CAG-3′) and an indexed pu1_P7 primer (5′-CAAGCAGAAGACGGCATACGAGAT
NNNNNNNNNGACCGTCGGCACTTTATCAATCTCGCTCCAAACC-3′), and
stopped before plateauing (six cycles). The libraries were sequenced on an Illumina
NextSeq 500/550 v2 300 cycle mid-output kit.
Analysis of STARR-seq screen. We aligned all sequencing reads to a reference
fasta file of our variants using BWA mem and extracted reads from error-free
molecules51. Each variant contained several different 5 nt barcodes added through
PCR. We counted the number of reads from each replicate for each
variant–barcode combination in the DNA and cDNA pool. If there were at least ten
DNA reads and at least one RNA read, we calculated an activity score as the log2
(number of RNA reads from the variant–barcode combination normalized to the
total number of RNA reads, divided by the number of DNA reads from the
variant–barcode combination normalized to the total number of DNA reads). We
then combined all variant–barcode activity scores from each replicate, and for any
variant with at least three different measurements, we averaged the activity score
for a final activity score for each variant. This resulted in activity scores for 2,537 of
the 3,210 alleles. In total, 1,132 of the 1,605 variants had activity scores for both
alleles. For each of the 1,132 variants with activity scores for both alleles, we tested
whether the two alleles drove different expression by performing a Mann–Whitney
U Test for each variant using SciPy v0.19.1 with Python v2.7.3. We then performed
a BH correction with an FDR= 0.10 to correct for multiple testing.
Luciferase assays. To generate the constructs for use in the luciferase reporter
gene assay, primers including either a KpnI, HindIII, or XhoI 5′ restriction were
designed to amplify DNA regions encompassing each of the six SNPs. Primer
sequences are listed in Supplementary Table 7. Template DNA consisted of a mix
of blood DNA from 20 patients. PCR products were TOPO cloned and positive
clones were selected using blue/white screening and genotyped by Sanger
sequencing to identify clones containing each of the two alleles at the six SNPs. It
was confirmed that no other polymorphisms were present in the cloned regions.
The required inserts were then sub-cloned using restriction enzymes into either the
pGL3-basic or pGL3-promoter luciferase reporter plasmid (Promega), depending
upon the predicted regulatory function of the region determined from the
ROADMAP Epigenome database. Positive clones were sequenced to ensure the
correct sequence of the constructs.
The Saos-2 human osteosarcoma cell line (ATCC) was transfected for the
luciferase assays. Twenty-four hours before transfection, Saos-2 cells were seeded at
a density of 8,000 per well in a 96-well plate. Cells were transfected with 100 ng of
pGL3 construct DNA and 1.5 ng of Renilla luciferase reporter vector pRL-TK
(Promega), using FuGene HD transfection reagent (Promega). After 24 h, the cells
were lysed, and luciferase activity was determined using a Dual-Luciferase Reporter
Assay System (Promega). Luminescence was measured using a GloMax-Multi
Detection System (Promega). Firefly luciferase activity was normalized to the
activity of Renilla luciferase. Six technical and 5–6 biologic repeats were performed
per construct. P-values were calculated using a Wilcoxon matched-pairs signed
rank test.
Allelic imbalance of rs4730222 in SW1353 cells. We first genotyped several
osteogenic and chondrogenic cell lines for rs4730222 (SW1353, Tc28a/2, Saos-2,
chondrogenic progenitor cells) using rs4730222_sangerF (5′-TACGCAGTTCGA
ATGAATGGGCTC-3′) and rs4730222_sangerR (5′-AGCTACAAAAACCTGGC
TGTCCAC-3′). PCR products were purified with a 1.5x AMPure cleanup and
Sanger sequenced with rs4730222_sangerF.
We then tested for allelic imbalance of rs4730222 in the isoforms expressing the
SNP in SW1353 (ATCC). We performed three independent DNA and RNA
extractions using the Qiagen ALLPrep DNA/RNA Mini Kit. DNA was eluted in 80
µL, and RNA was eluted in 30 µL. RNA was treated with TURBO DNase and
reverse transcribed with SuperScript III Reverse Transcriptase. We then amplified
the 5′-UTR around rs4730222 from each DNA and cDNA sample using KAPA
HiFi HotStart ReadyMix in a 50 µL reaction with 100 ng of DNA or 5 µL of cDNA
with HBP1_5UTR_F_pu1 (5′-CTAAATGGCTGTGAGAGAGCTCAGAGTCCGG
GCTGCGGTCACATGATG-3′) and HBP1_5UTR_R_pu1 (5′-ACTTTATCAATC
TCGCTCCAAACCAGCTACAAAAACCTGGCTGTCCAC-3′), and stopped DNA
reactions at 25 cycles and cDNA reactions at 32 cycles. Products were purified
using a 1.5x AMPure cleanup, and flow-cell adapters and indexes were added using
an indexed pu1_P5 primer and an indexed pu1_P7 primer. Libraries were spiked
into a Miseq v2 300 cycle run. Reads were aligned to a fasta reference file using
BWA mem, and the number of perfect reads coming from both alleles was
quantified from both DNA and cDNA from each replicate.
CRISPR knock-in of rs4730222 in Saos-2 cells. rs4730222 falls within a potential
Cas9 PAM site (5′-ACGCGATGAATGGCGAAAGAGGG-3′). We therefore
designed a guideRNA that would target rs4730222, so that the minor-allele donor
would not be re-cut. We ordered the following oligos from IDT: rs4730222_guideF
(5′-CACCGACGCGATGAATGGCGAAAGA-3′) and rs4730222_guideR (5′-AAA
CTCTTTCGCCATTCATCGCGTC-3′) and followed the Zhang lab protocol to
clone them into the px458 plasmid (SpCas9–2A-EGFP and single-guide RNA)52.
We created our donor vector in two steps. First, we amplified a 1,459 -bp region
around rs4730222 with the following primers, which also append 16 -bp homologous
sequence to puc19 onto each side of the amplicon: HBP1_puc19F (5′-TCGGTACCC
GGGGATCAAGTAGGAAAGTTTCGGTTGAGGAG-3′) and HBP1_puc19R (5′-TC
GACTCTAGAGGATCAACTGAACAGATGACCGACTCTACC-3). We then cloned
this into a linearized puc19 plasmid using Clontech’s In-Fusion HD Cloning Kit
following the manufacturer’s protocol, transformed into Stellar Competent cells, grew
up a single colony and extracted plasmid using the Zymo Research ZymoPURE
Plasmid Midiprep Kit. We then re-linearized the puc19-HBP1 wild-type plasmid via
PCR with puc19_HBP1-linF (5′-GTGGGGGATGGACTTGGCGTG-3′) and puc19-
HBP1-linR (5′-CTCCTCAACCGAAACTTTCCTACTT-3′). We also amplified a small
region around rs4730222, while mutating the SNP, using mut_insF (5′-AAGTAGGA
AAGTTTCGGTTGAGGAG-3′) and mut_insR (5′-CCAAGTCCATCCCCCACGCT
CTTTCGCCATTCATCGCG-3′). We then cloned the mutated insert into puc19-
HBP1-wt using the In-Fusion HD Cloning Kit and grew up a single colony with the
minor allele at rs4730222 flanked by 600–850 bp of homology on each side.
We transfected 1 million Saos-2 cells with 10 µg of our px458-rs4730222 guide
and 10 µg of our donor library containing the minor allele using the Neon
Transfection system as described above. Seventy-two hours post transfection, we
performed FACS on a BD FACS Aria III to isolate ~150,000 GFP+ cells
(transfected with px458), which we then expanded. On day 10 post transfection, we
extracted DNA and RNA, performed reverse transcription with Superscript III, and
amplified the region surrounding rs4730222 from both DNA (using
HBP1_5UTR_F_pu1 and HBP_DNA_Routside (5′-TAGGTGGGCAATCCTGGG
AGAAGGTAC-3′)), and RNA (using HBP1_5UTR_F_pu1 and
HBP_RNA_Routside (5′-TGCCAGATTCTGACTCACTATTTGC-3′)) in 50 µL
reactions using KAPA HiFi 2x ReadyMix. We then purified the PCR reactions with
a 1.5x AMPure cleanup, eluted in 50 uL, and used 1 µL in a nested reaction with
pu1L (5′-CTAAATGGCTGTGAGAGAGCTCAG-3′) and HBP1_5UTR_R_pu1.
Reactions were purified with a 1.5x AMPure cleanup, and flow-cell adapters and
indexes were added using an indexed pu1_P5 primer and an indexed pu1_P7
primer. Libraries were spiked into a Miseq v2 300 cycle run. Reads were aligned to
a fasta reference file using BWA mem, and the number of perfect reads coming
from both alleles was quantified from both DNA and cDNA from each replicate.
Allelic imbalance of rs4730222 in OA patients’ chondrocytes. Cartilage tissue
samples were obtained from OA patients who had undergone joint replacement
surgery at the Newcastle upon Tyne NHS Foundation Trust hospitals. The New-
castle and North Tyneside Research Ethics Committee granted ethical approval for
the collection, with each donor providing verbal and written informed consent
(REC reference number 14/NE/1212). Our patient ascertainment criterion has been
described in detail previously53,54. The cartilage was removed from the joint using a
scalpel and was collected distal to the OA lesion. The tissue samples were stored
frozen at −80 °C and ground to a powder using a Retsch Mixermill 200 (Retsch
Limited) under liquid nitrogen. Nucleic acids were then extracted from the ground
tissue using TRIzol reagent (Life Technologies) according to the manufacturer’s
instructions, with the upper aqueous phase separated for RNA isolation, while the
interphase and lower organic phase were used to isolate DNA. RNA was reverse
transcribed using the SuperScript First-Strand cDNA synthesis kit (Invitrogen).
Matched DNA and cDNA were amplified with KAPA HiFi 2x ReadyMix and SYBR
Green and halted before plateauing. The primers sequences were as follows:
5′-CTAAATGGCTGTGAGAGAGCTCAGAGTCCGGGCTGCGGTCACATG
ATG-3′ and 5′-ACTTTATCAATCTCGCTCCAAACCAGCTACAAAAACCTGG
CTGTCCAC-3′.
All samples were purified with a 1.5x AMPure cleanup following the
manufacturer’s instructions and eluted in 50 µL Qiagen Elution Buffer. One
microliter of purified product was then indexed for Illumina sequencing using an
indexed pu1_P5 primer and an indexed pu1_P7 primer. Libraries were spiked into
a Miseq v2 300 cycle run. Following our previously devised processing pipeline55,
reads were aligned to a fasta reference file using BWA mem51, and the number of
aligning reads coming from both alleles was quantified from both DNA and cDNA
from each replicate. For statistical analysis, a Mann–Whitney U test was performed
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comparing DNA versus RNA abundances of the minor allele for the 18 values (9
for DNA and 9 for RNA; averaged over three replicates for each of nine patients).
Electrophoretic mobility shift assays (EMSAs) of rs4730222. Nuclear protein
was extracted from SW1353 and Saos-2 cells as previously described56. For each
allele of rs4730222, forward and reverse single-stranded DY682-labeled oligonu-
cleotides (Eurofins MWG Operon), spanning 15 nt each side of the SNP (Sup-
plementary Table 4), were annealed to generate double stranded probes. EMSAs
were performed as previously described56.
Characterization of HBP1 rs4730222-containing isoforms. We designed the
following set of primers to differentiate between different HBP1 isoforms: major
(1stExonF: 5′-GTGTGGGAAGTGAAGACAAATCAGATGC-3′ and LastExonR:
5′-CTTCCACCTGTCACCAAGGATCACAC-3′), 5′-UTR (UTR_qPCR_F: 5′-CA
GTCTCCGCCTTTCAACCTATG-3′ and UTR_qPCR_R: 5′-ATGAACTCGAG
TGTAGAGTGCACAG-3′), Truncated (UTR_qPCR_F and Exon6_R: CCACCTC
ATTTTCACGGTAAGTAG-3′) and Full Len (UTR_qPCR_F and LastExonR). We
performed technical triplicates for each qPCR using KAPA Robust 2x Hotstart
Readymix with cDNA from wild-type SW1353 cells, letting the reaction go for 40
cycles. We then ran products on a gel, and differentiated between
ENST00000497535 and ENST00000485846 based both on size and Sanger
sequencing.
Lasso regression model to predict enhancer activity. For each candidate
enhancer, we computed a total of 853 features derived from either (i) the sequence
itself, or (ii) experimentally measured information, computed as a mean signal
extracted from the corresponding region of the human genome (Supplementary
Data 5, 6). The sequence-based features represent the conservation of the sequence,
general G/C content, predicted chromatin state, and likelihood of binding to an
assortment of transcription factors. In contrast, the experimentally derived features
represent empirical measurements of chromatin/epigenetic state and binding to
transcription factors. The features were derived from custom Perl scripts, the
UCSC genome browser57, DeepSEA58, DeepBind59, and ChIP-Atlas60.
Right-skewed data such as ChIP-seq and CAGE signal were log-transformed to
approximate a normal distribution, and each feature was then z-score normalized
to scale the features similarly. This enabled a direct comparison of coefficients
among features derived from the resulting linear models.
We trained a lasso regression model on each of 10-fold of the data55. A lasso
regression model was chosen specifically because it employs an L1 regularization
penalty, which leads to the selection of the fewest features that maximally explain
the data. The strength of the regularization was controlled by a single λ parameter,
which was optimized using 10-fold cross-validation on the entire data set. To
evaluate the most relevant features selected, we trained a lasso regression model on
the full data set and visualize the top 30 coefficients with the greatest magnitude
(Supplementary Fig. 2B). A full table of the selected features and their coefficients
are provided (Supplementary Data 6).
Data availability
All processed data are provided in supplementary data files. Raw data are available as
SRA accession PRJNA532491. The source data underlying Figs. 2a, 2b, 3b, and 3c and
Supplementary Figs 1, 2A, 3A, 4, 5, and 6 are provided as a Source Data file.
Received: 22 June 2018 Accepted: 29 April 2019
References
1. Breedveld, F. C. Osteoarthritis–the impact of a serious disease. Rheumatology
43, i4–i8 (2004).
2. Patwardhan, R. P. et al. High-resolution analysis of DNA regulatory
elements by synthetic saturation mutagenesis. Nat. Biotechnol. 27, 1173–1175
(2009).
3. Patwardhan, R. P. et al. Massively parallel functional dissection of mammalian
enhancers in vivo. Nat. Biotechnol. 30, 265–270 (2012).
4. Melnikov, A. et al. Systematic dissection and optimization of inducible
enhancers in human cells using a massively parallel reporter assay. Nat.
Biotechnol. 30, 271 (2012).
5. Arnold, C. D. et al. Genome-wide quantitative enhancer activity maps
identified by STARR-seq. Science 339, 1074–1077 (2013).
6. Tewhey, R. et al. Direct identification of hundreds of expression-modulating
variants using a multiplexed reporter assay. Cell 172, 1132–1134 (2018).
7. Ulirsch, J. C. et al. Systematic functional dissection of common genetic
variation affecting red blood cell traits. Cell 165, 1530–1545 (2016).
8. Liu, S. et al. Systematic identification of regulatory variants associated with
cancer risk. Genome Biol. 18, 194 (2017).
9. Vockley, C. M. et al. Massively parallel quantification of the regulatory effects
of noncoding genetic variation in a human cohort. Genome Res. 25,
1206–1214 (2015).
10. Consortium, A. & Others arcOGEN Collaborators, Zeggini, E.,
Panoutsopoulou, K, Southam, L, Rayner, NW et al. Identification of new
susceptibility loci for osteoarthritis (arcOGEN): a genome-wide association
study. Lancet 380, 815–823 (2012).
11. Kerkhof, H. J. M. et al. A genome-wide association study identifies an
osteoarthritis susceptibility locus on chromosome 7q22. Arthritis Rheum. 62,
499–510 (2010).
12. Day-Williams, A. G. et al. A variant in MCF2L is associated with
osteoarthritis. Am. J. Hum. Genet. 89, 446–450 (2011).
13. Meulenbelt, I. et al. Identification of DIO2 as a new susceptibility locus for
symptomatic osteoarthritis. Hum. Mol. Genet. 17, 1867–1875 (2008).
14. Meulenbelt, I. et al. Meta-analyses of genes modulating intracellular T3 bio-
availability reveal a possible role for the DIO3 gene in osteoarthritis
susceptibility. Ann. Rheum. Dis. 70, 164–167 (2011).
15. Styrkarsdottir, U. et al. Severe osteoarthritis of the hand associates with
common variants within the ALDH1A2 gene and with rare variants at 1p31.
Nat. Genet. 46, 498–502 (2014).
16. Evangelou, E. et al. The DOT1L rs12982744 polymorphism is associated with
osteoarthritis of the hip with genome-wide statistical significance in males.
Ann. Rheum. Dis. 72, 1264–1265 (2013).
17. Evangelou, E. et al. A meta-analysis of genome-wide association studies
identifies novel variants associated with osteoarthritis of the hip. Ann. Rheum.
Dis. 73, 2130–2136 (2014).
18. Miyamoto, Y. et al. A functional polymorphism in the 5′ UTR of GDF5
is associated with susceptibility to osteoarthritis. Nat. Genet. 39, 529–533
(2007).
19. den Hollander, W. et al. Genome-wide association and functional studies
identify a role for matrix Gla protein in osteoarthritis of the hand. Ann.
Rheum. Dis. 76, 2046–2053 (2017).
20. Panoutsopoulou, K. et al. Radiographic endophenotyping in hip osteoarthritis
improves the precision of genetic association analysis. Ann. Rheum. Dis. 76,
1199–1206 (2017).
21. Castaño-Betancourt, M. C. et al. Novel genetic variants for cartilage thickness
and hip osteoarthritis. PLoS Genet. 12, e1006260 (2016).
22. Yau, M. S. et al. Genome-wide association study of radiographic knee
osteoarthritis in North American Caucasians. Arthritis Rheuma. 69, 343–351
(2017).
23. Evans, D. S. et al. Genome-wide association and functional studies identify a
role for IGFBP3 in hip osteoarthritis. Ann. Rheum. Dis. 74, 1861–1867 (2015).
24. Valdes, A. M. et al. Genetic variation≥ in the SMAD3 gene is associated with
hip and knee osteoarthritis. Arthritis Rheum. 62, 2347–2352 (2010).
25. Rodriguez-Fontenla, C. et al. Assessment of osteoarthritis candidate genes in a
meta-analysis of nine genome-wide association studies. Arthritis Rheuma. 66,
940–949 (2014).
26. Casalone, E. et al. A novel variant in GLIS3 is associated with osteoarthritis.
Ann. Rheum. Dis. 77, 620–623 (2018).
27. Zengini, E. et al. Genome-wide analyses using UK Biobank data provide
insights into the genetic architecture of osteoarthritis. Nat. Genet. 50, 549–558
(2018).
28. Cotney, J. et al. The evolution of lineage-specific regulatory activities in the
human embryonic limb. Cell 154, 185–196 (2013).
29. Herlofsen, S. R. et al. Genome-wide map of quantified epigenetic changes
during in vitro chondrogenic differentiation of primary human mesenchymal
stem cells. BMC Genom. 14, 105 (2013).
30. Raine, E. V. A., Wreglesworth, N., Dodd, A. W., Reynard, L. N. & Loughlin, J.
Gene expression analysis reveals HBP1 as a key target for the osteoarthritis
susceptibility locus that maps to chromosome 7q22. Ann. Rheum. Dis. 71,
2020–2027 (2012).
31. Luyten, F. P., Tylzanowski, P. & Lories, R. J. Wnt signaling and osteoarthritis.
Bone 44, 522–527 (2009).
32. Berasi, S. P., Xiu, M., Yee, A. S. & Paulson, K. E. HBP1 repression of the
p47phox gene: cell cycle regulation via the NADPH oxidase. Mol. Cell. Biol.
24, 3011–3024 (2004).
33. Scott, J. L. et al. Superoxide dismutase downregulation in osteoarthritis
progression and end-stage disease. Ann. Rheum. Dis. 69, 1502–1510 (2010).
34. Liu, Y. et al. Chromatin accessibility landscape of articular knee cartilage
reveals aberrant enhancer regulation in osteoarthritis. Sci. Rep. 19, 15499
(2018).
35. Thierry-Mieg, D., Thierry-Mieg, J. & NCBI/NLM/NIH. AceView: Gene:HBP1,
a comprehensive annotation of human, mouse and worm genes with mRNAs
or ESTsAceView. https://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/av.
cgi?db=36a&c=Gene&l=HBP1 (2018).
36. Gee, F., Rushton, M. D., Loughlin, J. & Reynard, L. N. Correlation of the
osteoarthritis susceptibility variants that map to chromosome 20q13 with an
expression quantitative trait locus operating on NCOA3 and with functional
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10439-y
8 NATURE COMMUNICATIONS |         (2019) 10:2434 | https://doi.org/10.1038/s41467-019-10439-y | www.nature.com/naturecommunications
variation at the polymorphism rs116855380. Arthritis Rheumatol. 67,
2923–2932 (2015).
37. Shepherd, C. et al. Functional characterisation of the osteoarthritis genetic risk
residing at ALDH1A2 identifies rs12915901 as a key target variant. Arthritis
Rheumatol. https://doi.org/10.1002/art.40545 (2018).
38. Fishilevich, S. et al. Genic insights from integrated human proteomics in
GeneCards. Database. https://doi.org/10.1093/database/baw030 (2016).
39. Feng, H., Tillman, H., Wu, G., Davidoff, A. M. & Yang, J. Frequent epigenetic
alterations in polycomb repressive complex 2 in osteosarcoma cell lines.
Oncotarget 9, 27087–27091 (2018).
40. Kim, S. W. et al. Non-canonical Wnt signals are modulated by the Kaiso
transcriptional repressor and p120-catenin. Nat. Cell Biol. 6, 1212–1220
(2004).
41. Loeser, R. F., Goldring, S. R., Scanzello, C. R. & Goldring, M. B. Osteoarthritis:
A disease of the joint as an organ. Arthritis Rheum. 64, 1697–1707 (2012).
42. Pitsillides, A. A. & Beier, F. Cartilage biology in osteoarthritis–lessons from
developmental biology. Nat. Rev. Rheumatol. 7, 654–663 (2011).
43. Lefebvre, V. & Bhattaram, P. Vertebrate skeletogenesis. Curr. Top. Dev.
Biol. 90, 291–317 (2010).
44. Monteagudo, S. & Lories, R. J. Cushioning the cartilage: a canonical Wnt
restricting matter. Nat. Rev. Rheumatol. 13, 670–681 (2017).
45. Lories, R. J., Corr, M. & Lane, N. E. To Wnt or not to Wnt: the bone and joint
health dilemma. Nat. Rev. Rheumatol. 9, 328–339 (2013).
46. Zhu, M. et al. Inhibition of beta-catenin signaling in articular chondrocytes
results in articular cartilage destruction. Arthritis Rheum. 58, 2053–2064 (2008).
47. Zhu, M. et al. Activation of β-Catenin Signaling in Articular Chondrocytes
Leads to Osteoarthritis-Like Phenotype in Adult β-Catenin Conditional
Activation Mice. J. Bone Miner. Res. 24, 12–21 (2009).
48. Sampson, E. M. et al. Negative regulation of the Wnt-beta-catenin pathway by
the transcriptional repressor HBP1. EMBO J. 20, 4500–4511 (2001).
49. Wang, X., Hou, J., Quedenau, C. & Chen, W. Pervasive isoform‐specific
translational regulation via alternative transcription start sites in mammals.
Mol. Syst. Biol. 12, 875 (2016).
50. Reyes, A. & Huber, W. Alternative start and termination sites of transcription
drive most transcript isoform differences across human tissues. Nucleic Acids
Res. 46, 582–592 (2018).
51. Li, H. Aligning sequence reads, clone sequences and assembly contigs with
BWA-MEM. Preprint at http://arxiv.org/abs/1303.3997 (2013).
52. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat.
Protoc. 8, 2281–2308 (2013)
53. Southam, L. et al. An SNP in the 5′-UTR of GDF5 is associated with
osteoarthritis susceptibility in Europeans and with in vivo differences in
allelic expression in articular cartilage. Hum. Mol. Genet. 16, 2226–2232
(2007).
54. Egli, R. J. et al. Functional analysis of the osteoarthritis susceptibility-
associated GDF5 regulatory polymorphism. Arthritis Rheum. 60, 2055–2064
(2009).
55. Inoue, F. et al. A systematic comparison reveals substantial differences in
chromosomal versus episomal encoding of enhancer activity. Genome Res. 27,
38–52 (2017).
56. Syddall, C. M., Reynard, L. N., Young, D. A. & Loughlin, J. The identification
of trans-acting factors that regulate the expression of GDF5 via the
osteoarthritis susceptibility SNP rs143383. PLoS Genet. 9, e1003557 (2013).
57. Karolchik, D. et al. The UCSC genome browser database: 2014 update. Nucleic
Acids Res. 42, D764–D770 (2014).
58. Zhou, J. & Troyanskaya, O. G. Predicting effects of noncoding variants with
deep learning-based sequence model. Nat. Methods 12, 931–934 (2015).
59. Alipanahi, B., Delong, A., Weirauch, M. T. & Frey, B. J. Predicting the
sequence specificities of DNA- and RNA-binding proteins by deep learning.
Nat. Biotechnol. 33, 831–838 (2015).
60. Oki, S. et al. ChIP-Atlas: a data-mining suite powered by full integration of
public ChIP-seq data. EMBO Rep. 19, e46255 (2018).
Acknowledgements
The authors thank the Shendure and Loughlin labs, particularly J. Alexander, M. Gas-
perini, and S. Kim, for helpful discussions. This work was funded by grants from the
National Institutes of Health (UM1HG009408, R01CA197139, R01HG006768) to
J.S. J.C.K. was supported in part by 1F30HG009479 from the NHGRI. J.S. is an inves-
tigator of the Howard Hughes Medical Institute. S.J.R., C.S. and J.L. were supported by
Arthritis Research UK (grant 20771), and by the Medical Research Council and Arthritis
Research UK as part of the MRC-Arthritis Research UK Centre for Integrated Research
into Musculoskeletal Aging (CIMA, grant references JXR 10641, MR/P020941/1 and
MR/R502182/1).
Author contributions
The project was conceived and designed by J.C.K., A.K., J.S. and J.L. S.J.R. and C.S.
collated and generated the OA patient DNA and cDNA samples. J.L. compiled OA lead
variants. J.C.K. and A.K. performed the MPRA, CRISPR, and AEI experiments and
analyses. V.A. performed additional analysis and the lasso regression. S.J.R performed
luciferase assays. C.S. performed EMSA experiments. J.C.K., A.K. and J.S. wrote the
paper. All authors read and approved the final version of the paper.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
019-10439-y.
Competing interests: The authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Journal peer review information: Nature Communications thanks Stein Aerts and the
other anonymous reviewer(s) for their contribution to the peer review of this work.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10439-y ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2434 | https://doi.org/10.1038/s41467-019-10439-y | www.nature.com/naturecommunications 9
